What is the current Meningitis B Vaccine market size?

The Meningitis B Vaccine market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Meningitis B Vaccine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Meningitis B Vaccine market?

Key drivers include rising awareness, government initiatives, and advancements in vaccine technology.

What are the major challenges facing the Meningitis B Vaccine market?

Challenges include high development costs, stringent regulatory requirements, and vaccine hesitancy.

Which regions are leading the Meningitis B Vaccine market?

North America and Europe are current regional leaders, with emerging markets in Asia-Pacific.

Who are the top companies in the Meningitis B Vaccine market?

Leading companies include Pfizer, GlaxoSmithKline, and Sanofi, with emerging players in the market.

What future opportunities exist in the Meningitis B Vaccine market?

Future opportunities include expanding vaccine coverage, developing new vaccine formulations, and improving distribution channels.

How is technology impacting the Meningitis B Vaccine market?

Advances in vaccine technology, such as conjugate vaccines, are improving efficacy and driving market growth.

What is the current regulatory landscape for the Meningitis B Vaccine market?

The regulatory landscape is characterized by stringent approval processes, with emphasis on vaccine safety and efficacy.

What is the future outlook for the Meningitis B Vaccine market?

The future outlook is positive, with growing demand and increasing investments in vaccine development and distribution.

Meningitis B Vaccine Growth Trends & Strategic Outlook 2033

Meningitis B Vaccine by Application (Hospital, Clinic), by Types (MenACWY (Conjugate) Vaccine, MenB (Recombinant Protein) Vaccine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Meningitis B Vaccine Market Size | CAGR 12.8 Forecast 2033

Meningitis B Vaccine Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Meningitis B Vaccine Market Overview

The Meningitis B Vaccine market refers to the global industry involved in the development, production, and distribution of vaccines for preventing meningitis B, a serious and potentially life-threatening infection. The Meningitis B Vaccine market size is estimated to be around $1.4 billion in 2025, with a growth outlook that is expected to drive the market forward. As the market forecast suggests, the industry is poised for significant expansion, driven by increasing awareness about the importance of vaccination and government initiatives to improve public health. The industry expansion is expected to be fueled by advances in vaccine technology, rising demand from emerging economies, and growing investments in research and development.

Loading chart…

The Meningitis B Vaccine market is expected to grow at a CAGR of around 8% from 2026 to 2033, driven by macro drivers such as increasing government initiatives, advances in vaccine technology, and rising demand from emerging economies. Key forces shaping the industry include technology shifts towards more effective and efficient vaccine production, regulations and consumer behavior that prioritize public health and safety. The largest region in the Meningitis B Vaccine market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in healthcare infrastructure and growing awareness about the importance of vaccination.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.18 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Novartis; Pfizer; Sanofi Pasteur Inc; Wyeth Pharmaceuticals, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Meningitis B Vaccine market is poised for significant growth, driven by increasing awareness and demand for preventative measures against meningitis B. The Meningitis B Vaccine market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advancements in vaccine technology have led to the development of more effective and safer Meningitis B Vaccines, driving adoption rates and contributing to the growth of the Meningitis B Vaccine market.

Government initiatives and public-private partnerships aimed at improving vaccination coverage and reducing the incidence of meningitis B are expected to fuel the growth of the Meningitis B Vaccine market size.

Restraints2 items

High development costs and complex regulatory frameworks may hinder the entry of new players into the Meningitis B Vaccine market, potentially limiting growth and innovation.

Vaccine hesitancy and misinformation can negatively impact demand for Meningitis B Vaccines, affecting the overall growth forecast of the Meningitis B Vaccine market.

Opportunities2 items

Emerging markets present significant opportunities for the growth of the Meningitis B Vaccine market, driven by increasing healthcare expenditure and a rising awareness of preventative measures against meningitis B.

The development of combination vaccines that offer protection against multiple strains of meningitis, including meningitis B, can expand the Meningitis B Vaccine market size and attract new customers.

Challenges2 items

Supply chain disruptions and manufacturing capacity constraints can impact the availability of Meningitis B Vaccines, affecting the growth forecast of the Meningitis B Vaccine market and limiting access to these critical preventative measures.

Intense competition among established players in the Meningitis B Vaccine market can lead to pricing pressures, making it challenging for new entrants to achieve profitability and for existing players to maintain market share.

Market Segmentation

Loading chart…

The Application segment of the Meningitis B Vaccine market refers to the various uses of the vaccine, including infant, childhood, and adolescent immunization programs. This segment contributes significantly to the overall Meningitis B Vaccine market size, as it encompasses the primary target populations for vaccination. Understanding the application segment is crucial for Meningitis B Vaccine segmentation, as it helps manufacturers and healthcare providers tailor their strategies to specific age groups and immunization programs.

The Types segment of the Meningitis B Vaccine market includes meningococcal conjugate vaccines and meningococcal polysaccharide vaccines, among others. This segmentation is essential for market analysis, as different vaccine types have varying levels of effectiveness, safety profiles, and target populations. By examining the types segment, researchers can identify trends and patterns in vaccine development, approval, and adoption, ultimately informing market taxonomy and competitive landscape assessments.

Meningitis B Vaccine Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

MenACWY (Conjugate) Vaccine

MenB (Recombinant Protein) Vaccine

Regional Insights

Loading chart…

The Meningitis B Vaccine market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of vaccines, government policies, and investments in healthcare infrastructure.

In North America, key drivers include high ecosystem maturity, strong infrastructure, and favorable demographics. Europe is driven by policies supporting vaccination, adoption of new technologies, and a mature ecosystem. Asia Pacific's growth is fueled by increasing investments in healthcare, growing demographics, and improving infrastructure. Latin America's growth is driven by government policies, rising adoption, and expanding infrastructure. The Middle East & Africa region is expected to grow due to increasing investments, improving infrastructure, and rising adoption.

The regional forecast indicates that the Meningitis B Vaccine market will continue to grow, driven by these regional factors. Understanding these drivers is crucial for stakeholders to navigate the market and capitalize on opportunities. As the market continues to evolve, it is essential to monitor regional trends and market growth to make informed decisions.

Competitive Landscape

The Meningitis B Vaccine market is moderately consolidated, driven by a mix of global players and local/regional companies. The Meningitis B Vaccine competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals to maintain their market position, while local/regional companies rely on pricing and distribution strengths to compete.

Companies in the Meningitis B Vaccine market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Common competitive differentiators include technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have distinct strategic focuses:

GlaxoSmithKline: regional expansion

Novartis: vertical integration

Pfizer: premium pricing

Sanofi Pasteur Inc: OEM tie-ups

Wyeth Pharmaceuticals, Inc: innovation pipeline

GlaxoSmithKline: local manufacturing

Key Meningitis B Vaccine Companies5 items

GlaxoSmithKline

Novartis

Pfizer

Sanofi Pasteur Inc

Wyeth Pharmaceuticals, Inc.

Market Ecosystem

The Meningitis B Vaccine ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, midstream, and downstream. Upstream participants, such as raw material suppliers and technology providers, create the foundational elements of the vaccine. Midstream participants, including manufacturers and system integrators, transform these elements into the final product. Downstream participants, comprising distributors, service providers, and end users, facilitate the delivery and administration of the vaccine, ultimately capturing value for the ecosystem as a whole. Understanding the Meningitis B Vaccine ecosystem through a value chain analysis is crucial for identifying key control points, dependency risks, and opportunities for growth.

Raw material suppliers — provide vaccine components

Technology providers — develop vaccine technologies

OEMs / manufacturers — produce the vaccine

Distributors / channel partners — deliver the vaccine to healthcare facilities

Service providers / after-sales — administer the vaccine and provide support

End users / buyers — receive the vaccine

Regulators/standards bodies — oversee vaccine safety and efficacy

Value flows through the Meningitis B Vaccine ecosystem as participants interact and exchange goods, services, and information. Control points, such as regulatory approvals and distribution networks, influence the adoption and availability of the vaccine. Dependency risks, including input constraints and standards compliance, can impact the ecosystem's efficiency and responsiveness. Furthermore, switching costs, partnerships, and interoperability requirements can affect the flexibility and adaptability of ecosystem participants. As the ecosystem differs by region, due to varying regulatory frameworks, healthcare infrastructure, and market conditions, understanding these regional nuances is essential for navigating the complex Meningitis B Vaccine ecosystem.

Recent Industry Insights

The Meningitis B Vaccine industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have led to the development of new vaccine candidates. Additionally, there have been notable mergers & acquisitions, such as the acquisition of a vaccine manufacturer by a leading pharmaceutical company, which is expected to expand the production capacity of Meningitis B vaccines. Furthermore, regulatory changes in several countries have paved the way for the approval of new Meningitis B vaccine products, which is anticipated to drive growth in the market.

The shift in consumer trends towards preventive healthcare has also contributed to the growth of the Meningitis B Vaccine market. Moreover, funding rounds and expansions by vaccine manufacturers have enabled them to invest in research and development, leading to the launch of new products and technologies. These developments are expected to shape the future of the Meningitis B Vaccine industry, with the market anticipated to experience significant growth in the coming years.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Meningitis B Vaccine market outlook is that it presents a highly attractive opportunity for vaccine manufacturers, driven by increasing demand for preventive care and a growing awareness of the risks associated with meningitis B. The competitive intensity in this market is moderate, with a few established players and new entrants vying for market share.

The long-term outlook for this market is positive, with innovations in vaccine development and distribution expected to drive growth. However, the demand-supply balance may be affected by key risk factors, including regulatory challenges and supply chain disruptions. Overall, the Meningitis B Vaccine market is poised for significant growth, driven by increasing demand and advancements in vaccine technology.

11 items

1. Executive Summary

2. Meningitis B Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Meningitis B Vaccine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Meningitis B Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Meningitis B Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. MenACWY (Conjugate) Vaccine

6.2.2. MenB (Recombinant Protein) Vaccine

6.3. Global Meningitis B Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Meningitis B Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Meningitis B Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Meningitis B Vaccine Market Competition by Key Manufacturers

8.1. Global Meningitis B Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Meningitis B Vaccine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GlaxoSmithKline

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Pfizer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sanofi Pasteur Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Wyeth Pharmaceuticals, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Meningitis B Vaccine Market

Figure 4: Global Meningitis B Vaccine Market: Drivers

Figure 5: Global Meningitis B Vaccine Market: Challenges

Figure 6: Global Meningitis B Vaccine Market: Trends

Figure 7: Global Meningitis B Vaccine Market: Opportunity

Figure 8: Global Meningitis B Vaccine Market: Restraint

Figure 9: Global Meningitis B Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Meningitis B Vaccine Market Value (USD Million) By Region

Figure 15: Global Meningitis B Vaccine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Meningitis B Vaccine Market Value (USD Million) By Region

Figure 23: Global Meningitis B Vaccine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Meningitis B Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Meningitis B Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Meningitis B Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Meningitis B Vaccine Market Value (USD Million) By Region

Table 10: Global Meningitis B Vaccine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Meningitis B Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Meningitis B Vaccine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Meningitis B Vaccine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GlaxoSmithKline Basic Information And Sales Area

Table 31: GlaxoSmithKline. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Pfizer Basic Information And Sales Area

Table 35: Pfizer. Products Portfolio

Table 36: Sanofi Pasteur Inc Basic Information And Sales Area

Table 37: Sanofi Pasteur Inc. Products Portfolio

Table 38: Wyeth Pharmaceuticals, Inc. Basic Information And Sales Area

Table 39: Wyeth Pharmaceuticals, Inc.. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Meningitis B Vaccine Market Value (USD Million) By Region

Table 45: Global Meningitis B Vaccine Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Meningitis B Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.18 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Novartis; Pfizer; Sanofi Pasteur Inc; Wyeth Pharmaceuticals, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options